| dc.contributor.author | Nicastri, Emanuele et al. | |
| dc.date.accessioned | 2020-12-30T19:20:33Z | |
| dc.date.available | 2020-12-30T19:20:33Z | |
| dc.date.issued | 2020-03-16 | |
| dc.identifier.uri | https://doi.org/10.4081/idr.2020.8543 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/2446 | |
| dc.description.abstract | On January 9th, 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a diseases (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9th, 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; these recomendations should be considered as expert opinions, which may be modified according to newly produced literature data. | en_US |
| dc.language | English | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Infectious Diseases | en_US |
| dc.subject | Coronavirus | en_US |
| dc.subject | Coronavirus Infections | en_US |
| dc.subject | SARS-CoV-2 | en_US |
| dc.subject | Betacoronavirus | en_US |
| dc.subject | Therapeutics | en_US |
| dc.title | National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID-19 Clinical Management | en_US |
| eihealth.country | Others | en_US |
| eihealth.category | Clinical characterization and management | en_US |
| eihealth.type | Published Article | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
| dc.relation.ispartofjournal | Infectious Disease Reports | en_US |
